Kite, a division of Gilead Sciences, has been granted conditional marketing authorization by the European Medicines Agency for Tecartus, or brexucabtagene autoleucel, a chimeric antigen receptor T-cell therapy for relapsed or refractory mantle cell lymphoma. The treatment was approved in the US in July.
Kite CAR T-cell therapy wins conditional EU approval
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.